Alkermes (ALKS) Accumulated Expenses (2012 - 2026)
Alkermes' (ALKS) quarterly Accumulated Expenses came in at $53.4 million in Q1 2026, up 23.96% year-on-year from $43.1 million in Q1 2025, and down 35.2% on a QoQ basis from $82.4 million in Q4 2025.
Alkermes (ALKS) Accumulated Expenses (2012 - 2026) Analysis & Trends
Alkermes (ALKS) has 15 years of Accumulated Expenses data on file, last reported at $53.4 million in Q1 2026.
- On a quarterly basis, Accumulated Expenses rose 23.96% year-over-year to $53.4 million in Q1 2026; TTM through Mar 2026 was $53.4 million, a 23.96% increase from a year earlier, with the FY2025 full-year figure at $82.4 million, up 16.19% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $53.4 million, down from $82.4 million in the prior quarter.
- Over the last five years, Accumulated Expenses for ALKS reached as high as $282.3 million in Q1 2023 and fell as low as $43.1 million in Q1 2025.
- Historically, Accumulated Expenses has averaged $141.4 million across 5 years, with a median of $82.4 million in 2025.
- Across the five-year window, Accumulated Expenses soared 321.39% in 2023 and tumbled 82.11% in 2025, its largest moves.
- Year by year, Accumulated Expenses stood at $252.1 million in 2022, then plunged by 67.04% to $83.1 million in 2023, then retreated by 14.62% to $71.0 million in 2024, then climbed by 16.19% to $82.4 million in 2025, then tumbled by 35.2% to $53.4 million in 2026.
- Per Business Quant data, the three most recent Accumulated Expenses figures were $53.4 million in Q1 2026, $82.4 million in Q4 2025, and $67.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 53.43 Mn |
| Dec 31, 2025 | 82.45 Mn |
| Sep 30, 2025 | 67.20 Mn |
| Jun 30, 2025 | 56.54 Mn |
| Mar 31, 2025 | 43.10 Mn |
| Dec 31, 2024 | 70.96 Mn |
| Sep 30, 2024 | 282.02 Mn |
| Jun 30, 2024 | 49.39 Mn |
| Mar 31, 2024 | 240.88 Mn |
| Dec 31, 2023 | 83.11 Mn |
| Sep 30, 2023 | 238.47 Mn |
| Jun 30, 2023 | 222.77 Mn |
| Mar 31, 2023 | 282.26 Mn |
| Dec 31, 2022 | 252.12 Mn |
| Sep 30, 2022 | 60.92 Mn |
| Jun 30, 2022 | 52.87 Mn |
| Mar 31, 2022 | 265.17 Mn |
| Dec 31, 2021 | 77.26 Mn |
| Sep 30, 2021 | 68.00 Mn |
| Jun 30, 2021 | 204.56 Mn |